ClinicalTrials.gg
Enrolling by invitationNCT05844449Updated Apr 29, 2026

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

A Phase 3 interventional study of VNZ/TEZ/D-IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 37 sites in 10 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.

Planned enrollment
28th of 116
174 · median 73
Started
2023
with 4 others
Phase 3
62 of 125
1 open now
Registered
113th of 125
by date

Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 28th largest by planned enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2023, is one of 62 in phase 3, and was the 113th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Parts A and B:

  • Participants who have completed study drug treatment in the parent study (VX21-121-105; NCT Number: NCT05422222)

Part B:

-Meets at least 1 of the following criteria:

  • Completed study drug treatment in Part A
  • Had study drug interruption(s) in Part A, but did not permanently discontinue study drug and completed study visits up to the last scheduled visit of the treatment period of Part A

Key Exclusion Criteria:

  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment, or severe hepatic impairment that might pose an additional risk in administering study drug
  • History of solid organ, hematological transplantation, or cancer
  • History of drug intolerance in the parent study

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    VNZ/TEZ/D-IVA

    Part A: Participants (Cohort 1: 6 through 11 years of age (inclusive); Cohort 2: 2 through 5 years of age (inclusive) and Cohort 3: 1 to less than (\<) 2 years of age) will receive VNZ/TEZ/D-IVA once daily at doses determined based on their age and weight. The age range is based on date of informed consent in parent study. Part B: Participants in Cohort 1 who meet the eligibility criteria will receive VNZ/TEZ/D-IVA for an additional 96 weeks.

    Drug: VNZ/TEZ/D-IVA

Interventions

  • DrugVNZ/TEZ/D-IVA

    Fixed-dose combination tablets or granules for oral administration.

    Also known as: VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656, vanzacaftor/tezacaftor/deutivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

    Time frame: From Baseline up to Week 100

  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)

    Time frame: From Baseline up to Week 196

Secondary outcomes

  1. Part A (All Cohorts): Absolute Change in Sweat Chloride (SwCl)

    Time frame: From Baseline Through Week 96

  2. Part B: Absolute Change in Sweat Chloride (SwCl)

    Time frame: From Baseline Through Week 192

  3. Part A (Cohort 1): Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1)

    Time frame: From Baseline Through Week 100

  4. Part B: Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1)

    Time frame: From Baseline Through Week 196

  5. Part A (All Cohorts): Number of Pulmonary Exacerbation (PEx)

    Time frame: From Baseline Through Week 100

  6. Part B: Number of Pulmonary Exacerbation (PEx)

    Time frame: From Baseline Through Week 196

  7. Part A (All Cohorts): Number of CF- Related Hospitalizations

    Time frame: From Baseline Through Week 100

  8. Part B: Number of CF- Related Hospitalizations

    Time frame: From Baseline Through Week 196

  9. Part A (Cohort 1): Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score

    Time frame: From Baseline Through Week 100

  10. Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score

    Time frame: From Baseline Through Week 196

  11. Part A (Cohorts 1 and 2): Absolute Change in Body Mass Index (BMI)

    Time frame: From Baseline Through Week 100

  12. Part B: Absolute Change in Body Mass Index (BMI)

    Time frame: From Baseline Through Week 196

  13. Part A (Cohorts 1 and 2): Absolute Change in BMI-for-age Z-score

    Time frame: From Baseline Through Week 100

  14. Part B: Absolute Change in BMI-for-age Z-score

    Time frame: From Baseline Through Week 196

  15. Part A (Cohort 3): Absolute Change in Weight-for-length

    Time frame: From Baseline Through Week 100

  16. Part B: Absolute Change in Weight-for-length

    Time frame: From Baseline Through Week 196

  17. Part A (Cohort 3): Absolute Change in Weight-for-length Z-score

    Time frame: From Baseline Through Week 100

  18. Part B: Absolute Change in Weight-for-length Z-score

    Time frame: From Baseline Through Week 196

  19. Part A (All Cohorts): Absolute Change in Weight

    Time frame: From Baseline Through Week 100

  20. Part B: Absolute Change in Weight

    Time frame: From Baseline Through Week 196

  21. Part A (All Cohorts): Change in Weight-for-age Z-score

    Time frame: From Baseline Through Week 100

  22. Part B: Change in Weight-for-age Z-score

    Time frame: From Baseline Through Week 196

  23. Part A (Cohorts 1 and 2): Absolute Change in Height

    Time frame: From Baseline Through Week 100

  24. Part B: Absolute Change in Height

    Time frame: From Baseline Through Week 196

  25. Part A (Cohorts 1 and 2): Absolute Change in Height-for-age Z-score

    Time frame: From Baseline Through Week 100

  26. Part B: Absolute Change in Height-for-age Z-score

    Time frame: From Baseline Through Week 196

  27. Part A (Cohort 3): Absolute Change in Length

    Time frame: From Baseline Through Week 100

  28. Part B: Absolute Change in Length

    Time frame: From Baseline Through Week 196

  29. Part A (Cohort 3): Absolute Change in Length-for-age Z-score

    Time frame: From Baseline Through Week 100

  30. Part B: Absolute Change in Length-for-age Z-score

    Time frame: From Baseline Through Week 196

07

Study locations

37 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jul 2029, 71 months after the start.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 71 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
Aug 11, 2023
Primary completionEst.
Jul 30, 2029
CompletionEst.
Jul 30, 2029
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844449
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Aug 11, 2023
Primary completion
Jul 30, 2029 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Apr 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion